

For Research Use Only

Recombinant Human SLAMF7/CD319 protein (Myc Tag, His Tag)



Catalog Number: Eg0145

Basic Information

Species:
Human

Purity:
>90 %, SDS-PAGE

Tag:
Myc Tag, His Tag

Technical Specifications

Purity:

>90 %, SDS-PAGE

Endotoxin Level:

<0.1 EU/ μ g protein, LAL method

Source:

HEK293-derived Human SLAMF7 protein Ser23-Met226 (Accession# Q9NQ25-1) with a Myc tag and a His tag at the C-terminus.

GeneID:

57823

Accession:

Q9NQ25-1

Predicted Molecular Mass:

27.4 kDa

SDS-PAGE:

35-50 kDa, reducing (R) conditions

Formulation:

Lyophilized from 0.22 μ m filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.

Biological Activity

Not tested

Storage and Shipping

Storage:

It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

- Until expiry date, -20°C to -80°C as lyophilized proteins.
- 3 months, -20°C to -80°C under sterile conditions after reconstitution.

Shipping:

The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Reconstitution

Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.

Background

Signaling lymphocyte activation molecule (SLAM) family receptors is a group of type I transmembrane receptors belonging to the immunoglobulin superfamily. The SLAM family contains nine members that contain an extracellular segment comprising two or four Ig-like domains (V-like variable and C2-like constant), a transmembrane region and a cytoplasmic tail. They are involved in various physiological and pathological processes, including the regulation of immunological responses and the route of viral entry. SLAMF7, also known as CS1, CRACC or CD319, is expressed on NK cells, CD8+ T lymphocytes, B lymphocytes, and mature dendritic cells. It exerts both activating and inhibitory effects depending on the expression status of SAP or EAT-2. SLAMF7 is overexpressed in multiple myeloma and makes it a target for immunotherapy.


References

1. Joseph D Malaer, et al. (2017). Am J Cancer Res. 7(8):1637-1641.
2. Gregory Fouquet, et al. (2018). Oncotarget. 9(22):16248-16262.
3. Pooya Farhangnia, et al. (2023). Front Immunol. 14:1174138.

Synonyms

SLAMF7, SLAMF7/CD319, CD2-like receptor-activating cytotoxic cells, CD319, CRACC

Selected Validation Data



Purity of Recombinant Human SLAMF7 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

For technical support and original validation data for this product please contact

T: 027-87531629

E: Proteintech-CN@ptglab.com

W: ptgcn.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.